Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Lidocaine: Effect of Lidocaine in Chronic Cough

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01252225
Recruitment Status : Completed
First Posted : December 2, 2010
Last Update Posted : September 16, 2011
Information provided by (Responsible Party):
Manchester University NHS Foundation Trust

Brief Summary:

People cough in order to clear their airways. Most coughs are caused by viruses and settle down by themselves, but some people develop persistent coughing which can be anywhere from 8 weeks to several years. This is called chronic cough. People with chronic cough find the symptom distressing and it can have a major impact on their quality of life. Patients with chronic cough often report a sensation at the back of their throat which makes them feel an urge to cough. There is some evidence that Lidocaine (an anaesthetic used during medical procedures) can suppress a person's cough when given to patients via a nebuliser (a machine that turns liquid into a fine mist).

It is currently unknown whether using a local anaesthetic, such as Lidocaine, in the form of a throat spray would successfully suppress a person's cough. A throat spray would be an easier treatment option in chronic cough patients. Thus, the investigators research aims to compare cough rates, severity and urge to cough scores between Lidocaine throat spray and nebulised Lidocaine.

Condition or disease Intervention/treatment Phase
Chronic Cough Drug: 10 % Lidocaine Drug: 0.9% saline Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Lidocaine and Its Delivery in Patients With Chronic Cough
Study Start Date : February 2011
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cough

Arm Intervention/treatment
Active Comparator: Nebulised Lidocaine followed by Placebo throat spray Drug: 10 % Lidocaine
600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
Other Names:
  • Lidocaine
  • Lignocaine

Active Comparator: Nebulised Placebo followoed by Lidocaine Throat Spray Drug: 10 % Lidocaine
100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
Other Names:
  • Lidocaine
  • Lignocaine

Placebo Comparator: Nebulised placebo followed by placebo throat spray Drug: 0.9% saline
6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray

Primary Outcome Measures :
  1. Objective cough counts over 10 hours post dose. Change in Urge to cough and Visual Analogue Score (VAS). [ Time Frame: over 24 hours following treatment ]
    patients will wear a cough recorder device for a 24 hour period. The recordings will then be analysed to reveal how many times the patient coughed.

Secondary Outcome Measures :
  1. Heart rate [ Time Frame: over 2 hours ]
    to document any change in heart rate after treatment

  2. Mouth Numbness [ Time Frame: over 24 hours following treatment ]
    Duration of mouth numbness will be subjectively assessed by asking patients about the presence of mouth numbness and its duration after treatment.

  3. Electrocardiogram (ECG) [ Time Frame: 15 minutes after treatment ]
    ECG will be recorded before treatment and 15 minutes after treatment to rule out any arrhythmias

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects, age 18 years and over.
  • History of cough for more than 8 weeks.
  • Normal chest x ray
  • Chronic idiopathic cough or chronic cough resistant to treatment of specific triggers.

Exclusion Criteria:

  • Smoking status:

    • Current smokers
    • Ex smokers with history of smoking > 20 pack years or those who have given up < 6 months ago.
  • Prohibited medications:

    • Use of medications likely to suppress / affect cough including codeine, morphine, pregabalin, gabapentin, amitriptylline, angiotensin converting enzyme inhibitors (type 1) and baclofen.
    • Use of any anti-arrhythmic medication.
    • Use of cimetidine, beta blockers, or diuretics.
  • Cardiovascular conditions:

    • Sinoatrial disease, bradycardia or all types of heart blocks.
    • History of ischaemic heart disease or heart failure.
    • Clinically significant abnormal electrocardiogram (ECG) at Screening or Baseline.
    • History of cardiac surgery
  • Respiratory conditions:

    o Asthma.

  • Central nervous system / Peripheral nervous system conditions:

    • Epilepsy.
    • Myasthenia gravis.
  • Miscellaneous:

    • History of hepatic or renal dysfunction.
    • Porphyria
    • History of hypersensitivity to Lidocaine or related drugs.
    • Pregnancy or breast feeding.
    • Participation in another trial within the preceding 6 weeks.
    • Trauma or ulceration to oral mucosa.
    • History of chest or upper airway infection within the past 6 weeks.
    • Conditions which may affect cough response such as stroke, diabetes, Parkinson's Disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01252225

Layout table for location information
United Kingdom
University Hospital of South Manchester
Manchester, United Kingdom, M23 9LT
Sponsors and Collaborators
Manchester University NHS Foundation Trust
Layout table for investigator information
Principal Investigator: Ashley Woodcock, MD, FRCP University of Manchester
Layout table for additonal information
Responsible Party: Manchester University NHS Foundation Trust Identifier: NCT01252225    
Other Study ID Numbers: Lidocaine1
First Posted: December 2, 2010    Key Record Dates
Last Update Posted: September 16, 2011
Last Verified: September 2011
Keywords provided by Manchester University NHS Foundation Trust:
Chronic Cough
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action